Trial Profile
A randomized, double blind, placebo-controlled phase II study of testosterone replacement in men with non-metastatic castrate resistant prostate cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Testosterone (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jun 2011 Planned End Date changed from 1 Jan 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.